

## PRESCRIBING INFORMATION

Refer to Summary of Product Characteristics (SmPC) before prescribing, and for full prescribing information.

**JYSELECA**® ▼ filgotinib 100 mg or 200 mg film-coated tablets.

### Indications:

Jyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with lost response to, or were intolerant to either conventional therapy or a biologic agent.

**Dosage: Adults:** 200 mg once daily. Taken orally with/without food. It is recommended that tablets are swallowed whole.

#### Ulcerative colitis

In patients who do not show an adequate therapeutic benefit during the initial 10 weeks of treatment, 12 additional weeks of induction treatment with filgotinib 200 mg once daily may provide additional relief of symptoms (see SmPC). Patients who have not shown any therapeutic benefit after 22 weeks of treatment should discontinue filgotinib.

Laboratory Monitoring: Refer to the SmPC for information regarding laboratory monitoring and dose initiation or interruption.

#### Elderly: Ulcerative colitis

No dose adjustment is recommended for patients with ulcerative colitis up to 75 years of age. Filgotinib is not recommended in patients aged 75 years and older as there is no data in this population.

Renal impairment: No dose adjustment required in patients with estimated creatinine clearance (CrCl)  $\geq 60$  mL/min. A dose of 100 mg of filgotinib once daily is recommended for patients with moderate or severe renal impairment (CrCl 15 to  $< 60$  mL/min). Not recommended in patients with CrCl  $< 15$  mL/min.

Hepatic impairment: Mild/moderate hepatic impairment: No dose adjustment required. Severe hepatic impairment not recommended.

Children (<18 years) Safety and efficacy not yet been established.

**Contraindications:** Hypersensitivity to the active substance or to any of the excipients. Active tuberculosis (TB) or active serious infections. Pregnancy.

**Warnings/Precautions:** See SmPC for full information.

Immunosuppression: Combination use, with immunosuppressants e.g., ciclosporin, tacrolimus, biologics or other Janus kinase (JAK) inhibitors is not recommended as a risk of additive immunosuppression cannot be excluded.

Infections: Infections, including serious infections such as pneumonia and opportunistic infections e.g. tuberculosis (TB), oesophageal candidiasis, and cryptococcosis have been reported. Risk benefit

should be applied prior to initiating in patients with infection risk factors (see SmPC). Patients should be closely monitored for the development of signs and symptoms of infections during and after filgotinib treatment. Treatment should be interrupted if the patient is not responding to antimicrobial therapy, until infection is controlled. There is a higher incidence of serious infections in the elderly aged 75 years and older, caution should be used when treating this population.

Tuberculosis: Patients should be screened for TB before initiating filgotinib, and filgotinib should not be administered to patients with active TB.

Viral reactivation: Cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies (see SmPC). If a patient develops herpes zoster, filgotinib treatment should be temporarily interrupted until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should be performed.

Malignancy: Immunomodulatory medicinal products may increase the risk of malignancies. Malignancies were observed in clinical studies (see SmPC).

Fertility: In animal studies, decreased fertility, impaired spermatogenesis, and histopathological effects on male reproductive organs were observed (see SmPC). The potential effect of filgotinib on sperm production and male fertility in humans is currently unknown.

Haematological abnormalities: Do not start therapy, or temporarily stop, if Absolute Neutrophil Count (ANC)  $< 1 \times 10^9$  cells/L, ALC  $< 0.5 \times 10^9$  cells/L or haemoglobin  $< 8$  g/dL Temporarily stop therapy if these values are observed during routine patient management.

Vaccinations: Use of live vaccines during, or immediately prior to, filgotinib treatment is not recommended.

Lipids: Treatment with filgotinib was associated with dose dependent increases in lipid parameters, including total cholesterol, and high-density lipoprotein (HDL) levels, while low density lipoprotein (LDL) levels were slightly increased (see SmPC).

Cardiovascular risk: Ulcerative colitis patients have an increased risk for cardiovascular disorders. Patients should have risk factors (e.g., hypertension, hyperlipidaemia) managed as part of usual standard of care.

Venous thromboembolism: Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients receiving JAK inhibitors including filgotinib. Caution should be used in patients with risk factors for DVT/PE, such as older age, obesity, a medical history of DVT/PE, or patients undergoing surgery, and prolonged immobilisation.

Lactose content: Contains lactose; patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take filgotinib.

Pregnancy/Lactation: Filgotinib is contraindicated in pregnancy. Filgotinib should not be used during breastfeeding. Women of childbearing potential must use effective contraception during and for at least 1 week after cessation of treatment.

**Driving/Using machinery:** No or negligible influence, however dizziness has been reported, during treatment with Jyseleca (SmPC for full information)

**Side effects:** See SmPC for full information.

Common ( $\geq 1/100$  to  $< 1/10$ ): nausea, upper respiratory tract infection, urinary tract infection and dizziness.

Uncommon ( $\geq 1/1000$  to  $< 1/100$ ): herpes zoster, pneumonia, neutropenia hypercholesterolaemia, blood creatine phosphokinase increase,

**Serious side effects:** See SmPC for full information

**Legal category:** POM

**Pack:** 30 film-coated tablets/ bottle

**Price:** UK Basic NHS cost: £863.10 Ireland POA

**Marketing authorisation number(s):**

Jyseleca 100mg film-coated tablets

EU/1/20/1480/001

EU/1/20/1480/002

Jyseleca 200mg film-coated tablets

EU/1/20/1480/003

EU/1/20/1480/004

**Further information:**

Galapagos UK, Belmont House, 148 Belmont Road,  
Uxbridge UB8 1QS, United Kingdom

00800 7878 1345

[medicalinfo@glpg.com](mailto:medicalinfo@glpg.com).

Jyseleca<sup>®</sup> is a trademark.

**Date of Preparation:** January 2022

IE-UC-FIL-202201-00002

▼ **Additional monitoring required**

**Adverse events should be reported.**  
For Northern Ireland, reporting forms and information can be found at [yellowcard.mhra.gov.uk](http://yellowcard.mhra.gov.uk) or via the Yellow Card app (download from the Apple App Store or Google Play Store).  
Adverse events should also be reported to Galapagos via email to [DrugSafety.UK.Ireland@glpg.com](mailto:DrugSafety.UK.Ireland@glpg.com) or 00800 7878 1345

**Adverse events should be reported.**  
For Ireland, reporting forms and information can be found at [www.hpra.ie](http://www.hpra.ie) and can be reported to HPRA on +353 1 6764971.  
Adverse events should also be reported to Galapagos via email to [DrugSafety.UK.Ireland@glpg.com](mailto:DrugSafety.UK.Ireland@glpg.com) or 00800 7878 1345

